Skip to content
Catalyst

metforminWhat was measured

Measured, with no finding

946 endpoints

Show what was measuredHide what was measured
  • Body mass index change

    decreases

    metformin use resulted in a marked decrease in body mass index [-1.24 kg/m2 (95% CI: -1.70 to -0.77)]

    PMID 39509416 · one of two readings recorded this

  • mean weight change in kg, pooled across placebo-controlled trials

    -3.32 kg (95% CI -4.57 to -2.07)

    Not recorded as a finding: sentence carries a signed estimate with no direction word, and does not state the comparator contrast

    The mean weight change with metformin was -3.32 kg [95% confidence interval (CI): -4.57 to -2.07].

    PMID 39509416 · one of two readings recorded this

  • mean weight change in kg, pooled, metformin versus placebo in antipsychotic-treated patients

    -3.32 kg [95% CI: -4.57 to -2.07]

    Not recorded as a finding: Direction carried only as a signed estimate (-3.32 kg); body-mass node is total body mass under stated conditions and the abstract states no instrument or conditions

    The mean weight change with metformin was -3.32 kg [95% confidence interval (CI): -4.57 to -2.07].

    PMID 39509416 · one of two readings recorded this

  • Weight change

    decreases

    The mean weight change with metformin was -3.32 kg [95% confidence interval (CI): -4.57 to -2.07]

    PMID 39509416 · one of two readings recorded this

  • esophageal cancer incidence (GRADE profile)

    decreases, n = 12

    IEC | 12 | CS | Serious | Serious | NS | Serious | No | Small | No | 0.85(0.72,0.99) | Very low

    PMID 39774829 · one of two readings recorded this

  • esophageal cancer incidence (per study)

    decreases

    Chin-Hsiao Tseng, 2016, China | CS | < 21.47 | 304,229 | 16216/16216 | 25.03/50.87 | - | 8 | - | - | IEC | 0.56[0.33, 0.94]

    PMID 39774829 · one of two readings recorded this

  • esophageal cancer incidence (per study)

    no effect

    Claudia Becker, 2013, UK | CCS | >60 | 4,070 | 2040/2030 | - | - | 6 | - | - | IEC | 1.11[0.79, 1.54]

    PMID 39774829 · one of two readings recorded this

  • esophageal cancer incidence (per study)

    decreases

    Francesca Valent, 2015, Italian | CS | - | 109255 | 63119/75402 | - | - | 7 | - | - | IEC | 0.98[0.98,1.00]

    PMID 39774829 · one of two readings recorded this

  • esophageal cancer incidence (per study)

    no effect

    Harvey J. Murff, 2018, USA | CS | 24 | 84,434 | 42217/42217 | 50/50 | - | 6 | - | - | IEC | 0.99[0.63, 1.55]

    PMID 39774829 · one of two readings recorded this

  • esophageal cancer incidence (per study)

    decreases

    Joseph JY Sung, 2020, China | CS | 56.4 | 289,297 | 11,365/277,932 | - | - | 7 | - | - | IEC | 0.27[0.12, 0.59]

    PMID 39774829 · one of two readings recorded this

  • esophageal cancer incidence (per study)

    no effect

    Kao-Chi Cheng, 2012, China | CCS | - | 279 | 231/48 | - | - | 6 | - | - | IEC | 2.84[0.99,8.18]

    PMID 39774829 · one of two readings recorded this

  • esophageal cancer incidence (per study)

    no effect

    Konstantinos K. Tsilidis, 2014, UK | CS | 12 | 95,820 | 51484/18264 | - | - | 8 | - | - | IEC | 1.05[0.71, 1.56]

    PMID 39774829 · one of two readings recorded this

  • esophageal cancer incidence (per study)

    no effect

    Meei-Shyuan Lee, 2011, China | CS | 24 | 480,984 | 11212/4193 | 47.8/40.3 | - | 7 | - | - | IEC | 0.44[0.07, 2.61]

    PMID 39774829 · one of two readings recorded this

  • esophageal cancer incidence (per study)

    decreases

    Qiao-Li Wang, 2019, Sweden | CS | - | 4,527,633 | 5411,603/4116030 | 3.5 /5.3 | - | 8 | - | ESCC | IEC | 0.68[0.54, 0.85]

    PMID 39774829 · one of two readings recorded this

  • esophageal cancer incidence (per study)

    decreases

    Rikje Ruiter, 2012, Netherlands | CS | 12 | 85,289 | 52,698/32,591 | 30/30 | - | 7 | - | - | IEC | 0.90 [0.82, 0.97]

    PMID 39774829 · one of two readings recorded this

  • esophageal cancer incidence (per study)

    no effect

    Roy G. de Jong, 2017, Netherlands | CS | - | 57,114 | 37215/19899 | 376/457 | - | 8 | - | - | IEC | 0.90[0.48, 1.67]

    PMID 39774829 · one of two readings recorded this

  • esophageal cancer incidence (per study)

    no effect

    Tak Kyu Oh, 2019, South Korea | CS | 9.6 | 66,627 | 29974/36653 | - | - | 7 | - | - | IEC | 0.38 [0.13, 1.13]

    PMID 39774829 · one of two readings recorded this

  • esophageal cancer incidence

    decreases, p = 0.04

    The random effects model showed that compared with the control groups, metformin might decrease EC incidence (OR = 0.87, P = 0.04)

    PMID 39774829 · one of two readings recorded this

  • esophageal cancer incidence

    no effect, p = 0.88, n = 2

    BMI | >30 | 2 | 0.85 | 0% | Fixed | 1.02 [0.76, 1.38] | 0.88

    PMID 39774829 · one of two readings recorded this

  • esophageal cancer incidence

    no effect, p = 0.07, n = 9

    Non-metformin | 9 | <0.0001 | 76% | Random | 0.78 [0.59, 1.02] | 0.07

    PMID 39774829 · one of two readings recorded this

  • esophageal cancer incidence

    decreases, p = 0.02, n = 3

    Comparators | Sulfonylureas | 3 | 0. 7 | 0% | Fixed | 0.91 [0.84, 0.99] | 0.02

    PMID 39774829 · one of two readings recorded this

  • esophageal cancer incidence

    decreases, p = 0.03

    60≥ | 7& | 0.18 | 33% | Fixed | 0.92 [0.85, 0.99] | 0.03

    PMID 39774829 · one of two readings recorded this

  • esophageal cancer incidence

    decreases, p = 0.0001, n = 3

    Mean age | <60 | 3 | 0.72 | 0% | Fixed | 0.66 [0.53, 0.81] | <0.0001

    PMID 39774829 · one of two readings recorded this

  • esophageal cancer incidence

    decreases, p = 0.0001, n = 4

    Region | Asia | 4 * | 0.52 | 0% | Fixed | 0.44 [0.29, 0.65] | <0.0001

    PMID 39774829 · one of two readings recorded this

  • esophageal cancer incidence

    decreases, p = 0.0004

    Europe and America | 6# | 0.42 | 0% | Fixed | 0.98 [0.97, 0.99] | 0.0004

    PMID 39774829 · one of two readings recorded this

  • esophageal cancer incidence

    decreases, p = 0.0001, n = 3

    Sample size | ≥300000 | 3 | 0.72 | 0% | Fixed | 0.66 [0.53, 0.81] | <0.0001

    PMID 39774829 · one of two readings recorded this

  • esophageal cancer incidence

    decreases, p = 0.0004

    <300000 | 8& | 0.11 | 41% | Fixed | 0.98 [0.97, 0.99] | 0.0004

    PMID 39774829 · one of two readings recorded this

  • esophageal cancer incidence

    no effect, p = 0.6, n = 3

    adjusted | 3 | 0.92 | 0% | Fixed | 1.06 [0.85, 1.32] | 0.6

    PMID 39774829 · one of two readings recorded this

  • esophageal cancer incidence

    no effect, p = 0.6, n = 3

    Adjusted | 3# | 0.92 | 0% | Fixed | 1.06 [0.85, 1.32] | 0.6

    PMID 39774829 · one of two readings recorded this

  • esophageal cancer incidence

    decreases, p = 0.01, n = 9

    BMI | No adjusted | 9 | <0.0001 | 78% | Random | 0.81 [0.69, 0.95] | 0.01

    PMID 39774829 · one of two readings recorded this

  • esophageal cancer incidence

    no effect, p = 0.07, n = 8

    Smoking | No adjusted | 8 | 0.0004 | 74% | Random | 0.86 [0.73, 1.01] | 0.07

    PMID 39774829 · one of two readings recorded this

  • esophageal cancer incidence

    decreases

    No | 6& | 0.11 | 44% | Fixed | 0.81 [0.68, 0.95] | 001

    PMID 39774829 · one of two readings recorded this

  • esophageal cancer incidence

    no effect, p = 0.33, n = 5

    Time-related biases | Yes | 5 | 0.01 | 69% | Random | 0.94 [0.84, 1.06] | 0.33

    PMID 39774829 · one of two readings recorded this

  • esophageal cancer incidence

    decreases, p = 0.004, n = 4

    Use of aspirin | Yes | 4 | 0.14 | 45% | Fixed | 0.76 [0.63, 0.91] | 0.004

    PMID 39774829 · one of two readings recorded this

  • esophageal cancer incidence

    no effect, p = 0.09, n = 2

    Use of Insulin | Yes | 2 | 0.4 | 0% | Fixed | 0.49 [0.21, 1.11] | 0.09

    PMID 39774829 · one of two readings recorded this

  • esophageal cancer incidence

    decreases, p = 0.006, n = 3

    Use of statins | Yes | 3 | 0.15 | 47% | Fixed | 0.77 [0.64, 0.93] | 0.006

    PMID 39774829 · one of two readings recorded this

  • overall survival in esophageal cancer (GRADE profile)

    decreases, n = 5

    OS | 5 | CS | Serious | NS | NS | NS | No | Small | No | 0.87(0.80,0.95) | Low

    PMID 39774829 · one of two readings recorded this

  • overall survival in esophageal cancer patients with diabetes, pooled hazard ratio

    increases, HR 0.87, p = 0.002

    Not recorded as a finding: no outcome node for overall survival in a cancer population; progression-free-survival and patient-survival-rate nodes do not match a pooled HR for OS

    The results showed that metformin could increase the OS of EC patients with diabetes (HR 0.87, P = 0.002), as shown in Fig 4.

    PMID 39774829 · one of two readings recorded this

  • overall survival in esophageal cancer (per study)

    decreases

    Huang-He He, 2020, China | CS | - | 619 | 485/134 | - | 69.07%/77.61% | 8 | II-III (77.7%) | ESCC (100%) | OS | 0.89 [0.80, 0.99]

    PMID 39774829 · one of two readings recorded this

  • overall survival in esophageal cancer (per study)

    no effect

    L. E. A. M. M. Spierings, 2015, Netherlands | CS | - | 43 | 32/11 | - | 6 | T3(77.7%) N1-N2(71.1%) | Adenocarcinoma (68.3%) | OS | 0.49 [0.08, 2.92]

    PMID 39774829 · one of two readings recorded this

  • overall survival in esophageal cancer (per study)

    decreases

    L. Van De Voorde, 2015, Netherlands | CS | - | 196 | 19/177 | - | 21%/50.3% | 6 | T3 (68%) N0-N1 (80%) | Adenocarcinoma (78.1%) | OS | 0.35 [0.13, 0.97]

    PMID 39774829 · one of two readings recorded this

  • overall survival in esophageal cancer (per study)

    no effect

    Qiaoli Wang, 2023, Sweden | CS | 12 | 852 | 473/379 | - | 79.9%/90.7% | 8 | III-IV (59.3%) | Adenocarcinoma (57.6%) ESCC (37.0%) | OS | 0.86[0.75,1.00]

    PMID 39774829 · one of two readings recorded this

  • overall survival in esophageal cancer

    decreases, p = 0.002

    The results showed that metformin could increase the OS of EC patients with diabetes (HR 0.87, P = 0.002)

    PMID 39774829 · one of two readings recorded this

  • overall survival in esophageal cancer

    decreases, p = 0.02, n = 3

    ≤70 | 3 | 0.17 | 44% | Fixed | 0.88 [0.79, 0.98] | 0.02

    PMID 39774829 · one of two readings recorded this

  • overall survival in esophageal cancer

    no effect, p = 0.09, n = 1

    Age | >70 | 1 | - | - | - | 0.84 [0.69, 1.03] | 0.09

    PMID 39774829 · one of two readings recorded this

  • overall survival in esophageal cancer

    decreases, p = 0.02, n = 3

    BMI | <30 | 3 | 0.11 | 44% | Fixed | 0.88 [0.79, 0.98] | 0.02

    PMID 39774829 · one of two readings recorded this

  • overall survival in esophageal cancer

    no effect, p = 0.07, n = 3

    Histology | Adenocarcinoma | 3 | 0.18 | 42% | Fixed | 0.85 [0.72, 1.01] | 0.07

    PMID 39774829 · one of two readings recorded this

  • overall survival in esophageal cancer

    decreases, p = 0.02, n = 2

    Squamous cell carcinoma | 2 | 0.77 | 0% | Fixed | 0.89 [0.80, 0.98] | 0.02

    PMID 39774829 · one of two readings recorded this

  • overall survival in esophageal cancer

    decreases, p = 0.03, n = 1

    Asia | 1 | - | - | - | 0.89 [0.80, 0.99] | 0.03

    PMID 39774829 · one of two readings recorded this

  • overall survival in esophageal cancer

    decreases, p = 0.02, n = 3

    Region | Europe and America | 3 | 0.19 | 39% | Fixed | 0.84 [0.73, 0.97] | 0.02

    PMID 39774829 · one of two readings recorded this

  • overall survival in esophageal cancer

    decreases, p = 0.003, n = 2

    ≥500 | 2 | 0.71 | 0% | Fixed | 0.88 [0.81, 0.96] | 0.003

    PMID 39774829 · one of two readings recorded this

  • overall survival in esophageal cancer

    decreases, p = 0.003, n = 2

    Sample size | <500 | 2 | 0.75 | 0% | Fixed | 0.38 [0.16, 0.92] | 0.003

    PMID 39774829 · one of two readings recorded this

  • overall survival in esophageal cancer

    decreases, p = 0.01, n = 2

    Predominantly Female | 2 | 0.59 | 0% | Fixed | 0.88 [0.80, 0.98] | 0.01

    PMID 39774829 · one of two readings recorded this

  • overall survival in esophageal cancer

    no effect, p = 0.05, n = 3

    Sex | Predominantly male | 3 | 0.19 | 40% | Fixed | 0.85 [0.72, 1.00] | 0.05

    PMID 39774829 · one of two readings recorded this

  • overall survival in esophageal cancer

    decreases, p = 0.03, n = 1

    adjusted | 1 | - | - | - | 0.89 [0.80, 0.99] | 0.03

    PMID 39774829 · one of two readings recorded this

  • overall survival in esophageal cancer

    decreases, p = 0.02, n = 3

    BMI | No adjusted | 3 | 0.19 | 39% | Fixed | 0.84 [0.73, 0.97] | 0.02

    PMID 39774829 · one of two readings recorded this

  • overall survival in esophageal cancer

    decreases, p = 0.02, n = 3

    Smoking | No adjusted | 3 | 0.19 | 39% | Fixed | 0.84 [0.73, 0.97] | 0.02

    PMID 39774829 · one of two readings recorded this

  • overall survival in esophageal cancer

    decreases, p = 0.03, n = 2

    Surgery + NC | Yes | 2 | 0.75 | 0% | Fixed | 0.38 [0.16, 0.92] | 0.03

    PMID 39774829 · one of two readings recorded this

  • overall survival in esophageal cancer

    decreases, p = 0.02, n = 4

    Surgery | Yes | 4 | 0.25 | 26% | Fixed | 0.89 [0.80, 0.98] | 0.02

    PMID 39774829 · one of two readings recorded this

  • overall survival in esophageal cancer

    decreases, p = 0.03, n = 2

    Use of statins | Yes | 2 | 0.54 | 0% | Fixed | 0.86 [0.74, 0.99] | 0.03

    PMID 39774829 · one of two readings recorded this

  • overall survival in esophageal cancer

    no effect, p = 0.08, n = 1

    Without Surgery | Yes | 1 | - | - | - | 0.87 [0.75, 1.01] | 0.08

    PMID 39774829 · one of two readings recorded this

  • overall survival (OS) of esophageal cancer patients with diabetes, pooled hazard ratio

    HR 0.87, p = 0.002

    Not recorded as a finding: no_outcome_node: overall survival as a pooled time-to-event hazard ratio has no entry in the outcome list (patient-survival-rate is a proportion alive at a stated follow-up)

    The results showed that metformin could increase the OS of EC patients with diabetes (HR 0.87, P = 0.002), as shown in Fig 4.

    PMID 39774829 · one of two readings recorded this

  • death after stroke (survival status, longest follow-up), pooled OR, prestroke metformin use versus none in diabetic patients; also poor functional course (mRS 3-6) pooled OR 0.66

    decreases, OR=0.57, 95% CI: 0.51 to 0.64

    Not recorded as a finding: the supporting sentence never names the compound

    Individual ORs ranged from 0.16 (95% CI: 0.02 to 1.33) to 0.73 (95% CI: 0.47 to 1.13), and the pooled analysis indicated a 43% reduction in the probability of death after stroke (OR=0.57, 95% CI: 0.51 to 0.64, p<0.001).

    PMID 39819905 · one of two readings recorded this

  • Death after stroke (survival status)

    decreases, p = 0.001, n = 15908

    the pooled analysis indicated a 43% reduction in the probability of death after stroke (OR=0.57, 95% CI: 0.51 to 0.64, p<0.001)

    PMID 39819905 · one of two readings recorded this

  • Egger's test publication bias, functional outcome

    no effect, p = 0.503

    effect of metformin use on functional outcome (p=0.503)

    PMID 39819905 · one of two readings recorded this

  • Egger's test publication bias, survival status

    no effect, p = 0.608

    functional outcome (p=0.503) and survival status (p=0.608)

    PMID 39819905 · one of two readings recorded this

  • poor functional course after stroke (modified Rankin Scale 3-6), longest follow-up

    decreases, OR=0.66, 95% CI: 0.61 to 0.72

    Not recorded as a finding: mrs-0-2-90-days requires the 0-2 cut at 90 days; this pooled estimate is poor course (3-6) at the longest follow-up each study reported

    Individual ORs ranged from 0.49 (95% CI: 0.24 to 0.97) to 0.87 (95% CI: 0.72 to 1.05), and pooled analysis showed that prestroke metformin use could reduce the probability of poor course after stroke by 34% in DM patients (OR=0.66, 95% CI: 0.61 to 0.72, p<0.001).

    PMID 39819905 · one of two readings recorded this

  • Poor functional outcome after stroke (mRS 3-6)

    decreases, p = 0.001

    pooled analysis showed that prestroke metformin use could reduce the probability of poor course after stroke by 34% in DM patients (OR=0.66, 95% CI: 0.61 to 0.72, p<0.001)

    PMID 39819905 · one of two readings recorded this

  • fasting plasma glucose reduction SUCRA

    300 mg of canagliflozin (90%) was the best option for FPG reduction, followed by 10 mg of ertugliflozin (86%), 10 mg of henagliflozin (84%), 15 mg of ertugliflozin (82%) and 25 mg of ertugliflozin (80%)

    PMID 40010842 · one of two readings recorded this

  • fasting plasma glucose reduction SUCRA

    300 mg of canagliflozin (90%) was the best option for FPG reduction, followed by 10 mg of ertugliflozin (86%), 10 mg of henagliflozin (84%), 15 mg of ertugliflozin (82%) and 25 mg of ertugliflozin (80%)

    PMID 40010842 · one of two readings recorded this

  • fasting plasma glucose reduction SUCRA

    300 mg of canagliflozin (90%) was the best option for FPG reduction, followed by 10 mg of ertugliflozin (86%), 10 mg of henagliflozin (84%), 15 mg of ertugliflozin (82%) and 25 mg of ertugliflozin (80%)

    PMID 40010842 · one of two readings recorded this

  • fasting plasma glucose reduction SUCRA

    300 mg of canagliflozin (90%) was the best option for FPG reduction, followed by 10 mg of ertugliflozin (86%), 10 mg of henagliflozin (84%), 15 mg of ertugliflozin (82%) and 25 mg of ertugliflozin (80%)

    PMID 40010842 · one of two readings recorded this

  • fasting plasma glucose reduction SUCRA

    300 mg of canagliflozin (90%) was the best option for FPG reduction, followed by 10 mg of ertugliflozin (86%), 10 mg of henagliflozin (84%), 15 mg of ertugliflozin (82%) and 25 mg of ertugliflozin (80%)

    PMID 40010842 · one of two readings recorded this

  • fasting plasma glucose reduction

    decreases

    300 mg and 200 mg of canagliflozin, 10 mg and 25 mg of ertugliflozin, and 10 mg of henagliflozin (MD (95% CI), −2.02 (−2.50, −1.50), −1.83 (−2.63, −1.04), −1.96 (−2.69, −1.23), −1.84 (−2.57, −1.11), −1.89 (−2.54, −1.23), respectively)

    PMID 40010842 · one of two readings recorded this

  • fasting plasma glucose reduction

    decreases

    300 mg and 200 mg of canagliflozin, 10 mg and 25 mg of ertugliflozin, and 10 mg of henagliflozin (MD (95% CI), −2.02 (−2.50, −1.50), −1.83 (−2.63, −1.04), −1.96 (−2.69, −1.23), −1.84 (−2.57, −1.11), −1.89 (−2.54, −1.23), respectively)

    PMID 40010842 · one of two readings recorded this

  • fasting plasma glucose reduction

    no effect

    1 mg of empagliflozin, 12.5 mg of ipragliflozin, and 2.5 mg, 5 mg and 10 mg of luseogliflozin (MD (95% CI), −0.23 (−0.89, 0.44), −0.61 (−1.32, 0.12), −0.38 (−1.11, 0.34), −0.63 (−1.35, 0.09), −0.67 (−1.39, 0.05), respectively)

    PMID 40010842 · one of two readings recorded this

  • fasting plasma glucose reduction

    decreases

    300 mg and 200 mg of canagliflozin, 10 mg and 25 mg of ertugliflozin, and 10 mg of henagliflozin (MD (95% CI), −2.02 (−2.50, −1.50), −1.83 (−2.63, −1.04), −1.96 (−2.69, −1.23), −1.84 (−2.57, −1.11), −1.89 (−2.54, −1.23), respectively)

    PMID 40010842 · one of two readings recorded this

  • fasting plasma glucose reduction

    decreases

    300 mg and 200 mg of canagliflozin, 10 mg and 25 mg of ertugliflozin, and 10 mg of henagliflozin (MD (95% CI), −2.02 (−2.50, −1.50), −1.83 (−2.63, −1.04), −1.96 (−2.69, −1.23), −1.84 (−2.57, −1.11), −1.89 (−2.54, −1.23), respectively)

    PMID 40010842 · one of two readings recorded this

  • fasting plasma glucose reduction

    decreases

    300 mg and 200 mg of canagliflozin, 10 mg and 25 mg of ertugliflozin, and 10 mg of henagliflozin (MD (95% CI), −2.02 (−2.50, −1.50), −1.83 (−2.63, −1.04), −1.96 (−2.69, −1.23), −1.84 (−2.57, −1.11), −1.89 (−2.54, −1.23), respectively)

    PMID 40010842 · one of two readings recorded this

  • fasting plasma glucose reduction

    no effect

    1 mg of empagliflozin, 12.5 mg of ipragliflozin, and 2.5 mg, 5 mg and 10 mg of luseogliflozin (MD (95% CI), −0.23 (−0.89, 0.44), −0.61 (−1.32, 0.12), −0.38 (−1.11, 0.34), −0.63 (−1.35, 0.09), −0.67 (−1.39, 0.05), respectively)

    PMID 40010842 · one of two readings recorded this

  • fasting plasma glucose reduction

    no effect

    1 mg of empagliflozin, 12.5 mg of ipragliflozin, and 2.5 mg, 5 mg and 10 mg of luseogliflozin (MD (95% CI), −0.23 (−0.89, 0.44), −0.61 (−1.32, 0.12), −0.38 (−1.11, 0.34), −0.63 (−1.35, 0.09), −0.67 (−1.39, 0.05), respectively)

    PMID 40010842 · one of two readings recorded this

  • fasting plasma glucose reduction

    no effect

    1 mg of empagliflozin, 12.5 mg of ipragliflozin, and 2.5 mg, 5 mg and 10 mg of luseogliflozin (MD (95% CI), −0.23 (−0.89, 0.44), −0.61 (−1.32, 0.12), −0.38 (−1.11, 0.34), −0.63 (−1.35, 0.09), −0.67 (−1.39, 0.05), respectively)

    PMID 40010842 · one of two readings recorded this

  • fasting plasma glucose reduction

    no effect

    1 mg of empagliflozin, 12.5 mg of ipragliflozin, and 2.5 mg, 5 mg and 10 mg of luseogliflozin (MD (95% CI), −0.23 (−0.89, 0.44), −0.61 (−1.32, 0.12), −0.38 (−1.11, 0.34), −0.63 (−1.35, 0.09), −0.67 (−1.39, 0.05), respectively)

    PMID 40010842 · one of two readings recorded this

  • genital infections

    increases

    only 10 mg of empagliflozin increased the incidence of GI (OR (95% CI), 12.73 (1.37, 437.17))

    PMID 40010842 · one of two readings recorded this

  • HbA1c reduction SUCRA

    15 mg of ertugliflozin (81%) ranked the highest in reducing HbA1c, followed by 10 mg of henagliflozin (80%), 300 mg of canagliflozin (77%), 5 mg of ertugliflozin (76%) and 5 mg of henagliflozin (76%)

    PMID 40010842 · one of two readings recorded this

  • HbA1c reduction SUCRA

    15 mg of ertugliflozin (81%) ranked the highest in reducing HbA1c, followed by 10 mg of henagliflozin (80%), 300 mg of canagliflozin (77%), 5 mg of ertugliflozin (76%) and 5 mg of henagliflozin (76%)

    PMID 40010842 · one of two readings recorded this

  • HbA1c reduction SUCRA

    15 mg of ertugliflozin (81%) ranked the highest in reducing HbA1c, followed by 10 mg of henagliflozin (80%), 300 mg of canagliflozin (77%), 5 mg of ertugliflozin (76%) and 5 mg of henagliflozin (76%)

    PMID 40010842 · one of two readings recorded this

  • HbA1c reduction SUCRA

    15 mg of ertugliflozin (81%) ranked the highest in reducing HbA1c, followed by 10 mg of henagliflozin (80%), 300 mg of canagliflozin (77%), 5 mg of ertugliflozin (76%) and 5 mg of henagliflozin (76%)

    PMID 40010842 · one of two readings recorded this

  • HbA1c reduction SUCRA

    15 mg of ertugliflozin (81%) ranked the highest in reducing HbA1c, followed by 10 mg of henagliflozin (80%), 300 mg of canagliflozin (77%), 5 mg of ertugliflozin (76%) and 5 mg of henagliflozin (76%)

    PMID 40010842 · one of two readings recorded this

  • HbA1c reduction

    decreases

    10 mg and 5 mg of henagliflozin, 15 mg and 25 mg of ertugliflozin, and 300 mg of canagliflozin showed reductions of −0.80% (−1.26, −0.34), −0.76% (−1.22, −0.30), −0.78% (−1.10, −0.46), −0.74% (−1.22, −0.27) and −0.74% (−1.07, −0.40), respectively

    PMID 40010842 · one of two readings recorded this

  • HbA1c reduction

    no effect

    2.5 mg of dapagliflozin and 1 mg and 5 mg of empagliflozin (MD (95% CI), −0.37 (−0.78, 0.05), −0.16 (−0.58, 0.26) and −0.30 (−0.72, 0.12), respectively)

    PMID 40010842 · one of two readings recorded this

  • HbA1c reduction

    no effect

    2.5 mg of dapagliflozin and 1 mg and 5 mg of empagliflozin (MD (95% CI), −0.37 (−0.78, 0.05), −0.16 (−0.58, 0.26) and −0.30 (−0.72, 0.12), respectively)

    PMID 40010842 · one of two readings recorded this

  • HbA1c reduction

    no effect

    2.5 mg of dapagliflozin and 1 mg and 5 mg of empagliflozin (MD (95% CI), −0.37 (−0.78, 0.05), −0.16 (−0.58, 0.26) and −0.30 (−0.72, 0.12), respectively)

    PMID 40010842 · one of two readings recorded this

  • HbA1c reduction

    decreases

    10 mg and 5 mg of henagliflozin, 15 mg and 25 mg of ertugliflozin, and 300 mg of canagliflozin showed reductions of −0.80% (−1.26, −0.34), −0.76% (−1.22, −0.30), −0.78% (−1.10, −0.46), −0.74% (−1.22, −0.27) and −0.74% (−1.07, −0.40), respectively

    PMID 40010842 · one of two readings recorded this

  • HbA1c reduction

    decreases

    10 mg and 5 mg of henagliflozin, 15 mg and 25 mg of ertugliflozin, and 300 mg of canagliflozin showed reductions of −0.80% (−1.26, −0.34), −0.76% (−1.22, −0.30), −0.78% (−1.10, −0.46), −0.74% (−1.22, −0.27) and −0.74% (−1.07, −0.40), respectively

    PMID 40010842 · one of two readings recorded this

  • HbA1c reduction

    decreases

    10 mg and 5 mg of henagliflozin, 15 mg and 25 mg of ertugliflozin, and 300 mg of canagliflozin showed reductions of −0.80% (−1.26, −0.34), −0.76% (−1.22, −0.30), −0.78% (−1.10, −0.46), −0.74% (−1.22, −0.27) and −0.74% (−1.07, −0.40), respectively

    PMID 40010842 · one of two readings recorded this

  • HbA1c reduction

    decreases

    10 mg and 5 mg of henagliflozin, 15 mg and 25 mg of ertugliflozin, and 300 mg of canagliflozin showed reductions of −0.80% (−1.26, −0.34), −0.76% (−1.22, −0.30), −0.78% (−1.10, −0.46), −0.74% (−1.22, −0.27) and −0.74% (−1.07, −0.40), respectively

    PMID 40010842 · one of two readings recorded this

  • HbA1c reduction

    decreases

    300 mg of canagliflozin, 5 mg and 15 mg of ertugliflozin, and 10 mg of henagliflozin (MD (95% CI), −0.58% (−1.12, −0.04), −0.57% (−1.08, −0.06), −0.62% (−1.15, −0.09) and −0.64% (−1.27, −0.02), respectively)

    PMID 40010842 · one of two readings recorded this

  • HbA1c reduction

    decreases

    300 mg of canagliflozin, 5 mg and 15 mg of ertugliflozin, and 10 mg of henagliflozin (MD (95% CI), −0.58% (−1.12, −0.04), −0.57% (−1.08, −0.06), −0.62% (−1.15, −0.09) and −0.64% (−1.27, −0.02), respectively)

    PMID 40010842 · one of two readings recorded this

  • HbA1c reduction

    decreases

    300 mg of canagliflozin, 5 mg and 15 mg of ertugliflozin, and 10 mg of henagliflozin (MD (95% CI), −0.58% (−1.12, −0.04), −0.57% (−1.08, −0.06), −0.62% (−1.15, −0.09) and −0.64% (−1.27, −0.02), respectively)

    PMID 40010842 · one of two readings recorded this

  • HbA1c reduction

    decreases

    300 mg of canagliflozin, 5 mg and 15 mg of ertugliflozin, and 10 mg of henagliflozin (MD (95% CI), −0.58% (−1.12, −0.04), −0.57% (−1.08, −0.06), −0.62% (−1.15, −0.09) and −0.64% (−1.27, −0.02), respectively)

    PMID 40010842 · one of two readings recorded this

  • hypoglycaemia incidence

    increases

    5 mg and 50 mg of empagliflozin, 5 mg and 15 mg of ertugliflozin, and 25 mg of janagliflozin exhibited higher incidence of hypoglycaemia (OR (95% CI), 6.00×106 (16.54, 7.12×1015), 1.36×106 (2.35, 1.55×1015), 2.29 (1.02, 6.18), 2.56 (1.09, 7.18), 2.50×106 (6.38, 1.88×1022) respectively)

    PMID 40010842 · one of two readings recorded this

  • hypoglycaemia incidence

    increases

    5 mg and 50 mg of empagliflozin, 5 mg and 15 mg of ertugliflozin, and 25 mg of janagliflozin exhibited higher incidence of hypoglycaemia (OR (95% CI), 6.00×106 (16.54, 7.12×1015), 1.36×106 (2.35, 1.55×1015), 2.29 (1.02, 6.18), 2.56 (1.09, 7.18), 2.50×106 (6.38, 1.88×1022) respectively)

    PMID 40010842 · one of two readings recorded this

  • total adverse events

    increases

    10 mg of henagliflozin was associated with increased AEs (OR (95% CI), 2.29 (1.29, 4.14))

    PMID 40010842 · one of two readings recorded this

  • weight loss SUCRA

    300 mg of canagliflozin (97%) demonstrated best efficacy in WL, followed by 20 mg of bexagliflozin (85%), 10 mg of ertugliflozin (80%), 100 mg of canagliflozin (79%) and 0.3 mg of enavogliflozin (77%)

    PMID 40010842 · one of two readings recorded this

  • weight loss SUCRA

    300 mg of canagliflozin (97%) demonstrated best efficacy in WL, followed by 20 mg of bexagliflozin (85%), 10 mg of ertugliflozin (80%), 100 mg of canagliflozin (79%) and 0.3 mg of enavogliflozin (77%)

    PMID 40010842 · one of two readings recorded this

  • weight loss SUCRA

    300 mg of canagliflozin (97%) demonstrated best efficacy in WL, followed by 20 mg of bexagliflozin (85%), 10 mg of ertugliflozin (80%), 100 mg of canagliflozin (79%) and 0.3 mg of enavogliflozin (77%)

    PMID 40010842 · one of two readings recorded this

  • weight loss SUCRA

    300 mg of canagliflozin (97%) demonstrated best efficacy in WL, followed by 20 mg of bexagliflozin (85%), 10 mg of ertugliflozin (80%), 100 mg of canagliflozin (79%) and 0.3 mg of enavogliflozin (77%)

    PMID 40010842 · one of two readings recorded this

  • weight loss SUCRA

    300 mg of canagliflozin (97%) demonstrated best efficacy in WL, followed by 20 mg of bexagliflozin (85%), 10 mg of ertugliflozin (80%), 100 mg of canagliflozin (79%) and 0.3 mg of enavogliflozin (77%)

    PMID 40010842 · one of two readings recorded this

  • weight loss

    no effect

    1 mg of empagliflozin and 12.5 mg of ipragliflozin (MD (95% CI), −0.57 (−1.38, 0.23), −0.40 (−1.27, 0.48), respectively)

    PMID 40010842 · one of two readings recorded this

  • weight loss

    no effect

    1 mg of empagliflozin and 12.5 mg of ipragliflozin (MD (95% CI), −0.57 (−1.38, 0.23), −0.40 (−1.27, 0.48), respectively)

    PMID 40010842 · one of two readings recorded this

  • class 3 obesity prevalence

    Almost all patients prescribed metformin were overweight or obese (94.8%), and prescription rates were highest in those with class 3 obesity (46.5%)

    PMID 40274755 · one of two readings recorded this

  • class 3 obesity prevalence

    Among patients who did not receive a metformin prescription order, the overall proportion with overweight/obesity and those with class 3 obesity was comparatively smaller (87.7% and 29.6%, respectively)

    PMID 40274755 · one of two readings recorded this

  • diabetes incidence

    n = 59232

    A total of 5,314 (9.0%) of patients developed diabetes (identified by diagnosis code or two glycemic tests) during the 5-year study period

    PMID 40274755 · one of two readings recorded this

  • diabetes progression timing

    < 1 year | 1,955 (32.6)

    PMID 40274755 · one of two readings recorded this

  • diabetes progression timing

    1–3 years | 2,420 (40.4)

    PMID 40274755 · one of two readings recorded this

  • diabetes progression timing

    3–5 years | 939 (15.7)

    PMID 40274755 · one of two readings recorded this

  • diabetes progression timing

    5 + years | 683 (11.4)

    PMID 40274755 · one of two readings recorded this

  • metformin prescription association with ethnicity

    p = 0.28

    The bivariate association of patient characteristics with metformin prescription status was significant for every variable except ethnicity (p = 0.28)

    PMID 40274755 · one of two readings recorded this

  • metformin prescription

    n = 57014

    Total | 57,014 | 1,699 (3.0) | 53,666 | 3,259 (6.1)

    PMID 40274755 · one of two readings recorded this

  • metformin prescription

    n = 53666

    Total | 57,014 | 1,699 (3.0) | 53,666 | 3,259 (6.1)

    PMID 40274755 · one of two readings recorded this

  • metformin prescription

    18–29 Years | 1.08 (0.94–1.24)

    PMID 40274755 · one of two readings recorded this

  • metformin prescription

    30–39 Years | 0.94 (0.83–1.06)

    PMID 40274755 · one of two readings recorded this

  • metformin prescription

    40–49 Years | 0.88 (0.79–0.99)

    PMID 40274755 · one of two readings recorded this

  • metformin prescription

    50–59 Years | 1.04 (0.92–1.16)

    PMID 40274755 · one of two readings recorded this

  • metformin prescription

    n = 14980

    Age < 60 years & Class 2 or 3 obese | 14,980 | 682 (4.5) | 13,974 | 1,320 (9.4)

    PMID 40274755 · one of two readings recorded this

  • metformin prescription

    n = 13974

    Age < 60 years & Class 2 or 3 obese | 14,980 | 682 (4.5) | 13,974 | 1,320 (9.4)

    PMID 40274755 · one of two readings recorded this

  • metformin prescription

    n = 47797

    Age < 60 years | 47,797 | 1,368 (2.9) | 43,048 | 2,643 (6.1)

    PMID 40274755 · one of two readings recorded this

  • metformin prescription

    n = 43048

    Age < 60 years | 47,797 | 1,368 (2.9) | 43,048 | 2,643 (6.1)

    PMID 40274755 · one of two readings recorded this

  • metformin prescription

    n = 17484

    Class 2 or 3 obese | 17,484 | 770 (4.4) | 16,210 | 1,495 (9.2)

    PMID 40274755 · one of two readings recorded this

  • metformin prescription

    n = 16210

    Class 2 or 3 obese | 17,484 | 770 (4.4) | 16,210 | 1,495 (9.2)

    PMID 40274755 · one of two readings recorded this

  • metformin prescription

    Hispanic | 1.00 (0.90–1.11)

    PMID 40274755 · one of two readings recorded this

  • metformin prescription

    Unknown | 0.95 (0.75–1.19)

    PMID 40274755 · one of two readings recorded this

  • metformin prescription

    ICD code | 0.84 (0.74–0.95)**

    PMID 40274755 · one of two readings recorded this

  • metformin prescription

    Medicare | 1.12 (0.95–1.32)

    PMID 40274755 · one of two readings recorded this

  • metformin prescription

    Private | 1.11 (0.98–1.25)

    PMID 40274755 · one of two readings recorded this

  • metformin prescription

    Uninsured | 1.05 (0.95–1.17)

    PMID 40274755 · one of two readings recorded this

  • metformin prescription

    Unknown | 0.73 (0.65–0.82)**

    PMID 40274755 · one of two readings recorded this

  • metformin prescription

    Another | 0.49 (0.35–0.68)**

    PMID 40274755 · one of two readings recorded this

  • metformin prescription

    Asian | 0.65 (0.52–0.80)**

    PMID 40274755 · one of two readings recorded this

  • metformin prescription

    Black | 0.76 (0.69–0.85)**

    PMID 40274755 · one of two readings recorded this

  • metformin prescription

    Unknown | 0.54 (0.48–0.61)**

    PMID 40274755 · one of two readings recorded this

  • metformin prescription

    Female | 1.09 (1.00–1.18)*

    PMID 40274755 · one of two readings recorded this

  • metformin prescription

    Class 1 obese | 2.29 (1.93–2.72)**

    PMID 40274755 · one of two readings recorded this

  • metformin prescription

    Class 2 or 3 obese | 3.75 (3.18–4.44)**

    PMID 40274755 · one of two readings recorded this

  • metformin prescription

    greater multivariable odds of metformin prescription were observed among those with overweight (OR:1.66 [CI: 1.39–1.98])

    PMID 40274755 · one of two readings recorded this

  • metformin prescription

    Underweight | 0.65 (0.26–1.59)

    PMID 40274755 · one of two readings recorded this

  • overweight or obesity prevalence

    Almost all patients prescribed metformin were overweight or obese (94.8%), and prescription rates were highest in those with class 3 obesity (46.5%)

    PMID 40274755 · one of two readings recorded this

  • overweight or obesity prevalence

    Among patients who did not receive a metformin prescription order, the overall proportion with overweight/obesity and those with class 3 obesity was comparatively smaller (87.7% and 29.6%, respectively)

    PMID 40274755 · one of two readings recorded this

  • receipt of a metformin prescription order within 1 and 5 years of prediabetes diagnosis, by patient BMI, race, sex and insurance status

    Not recorded as a finding: the compound is what was measured, not what was given

    Overall, 3.0% and 6.1% of FQHC patients with prediabetes received a metformin prescription within one and five years of their prediabetes identification, respectively (Table 3).

    PMID 40274755 · one of two readings recorded this

  • White race proportion

    White patients constituted 49.8% of the sample and accounted for 57.3% of patients who received a metformin prescription

    PMID 40274755 · one of two readings recorded this

  • All-cause mortality

    decreases, p = 0.001, n = 733873

    The pooled RR was 0.79 (95% CI: 0.71–0.88; p<0.001)

    PMID 40323973 · one of two readings recorded this

  • All-cause mortality

    no effect

    Bazo-Alvarez JC | 2021 | Type 2 diabetes patients in second antidiabetic drug | 3.5 | MACE, Death | 0.94(0.81-1.10) | 0.97(0.81-1.16)

    PMID 40323973 · one of two readings recorded this

  • All-cause mortality

    decreases

    Cho YY | 2018 | All patients with T2Dwho initiated second-line treatment | 5.2 | Death | – | 0.59(0.36-0.98)

    PMID 40323973 · one of two readings recorded this

  • All-cause mortality

    decreases

    Eriksson JW | 2016 | All patients with T2D in Sweden who initiated second-line treatment | 3 | Death | – | 0.70(0.56-0.87)

    PMID 40323973 · one of two readings recorded this

  • All-cause mortality

    decreases

    Franchi M | 2024 | Type 2 diabetes patients who received DPP-4is or SUs in addition to metformin | 5.61 | MACE, Death | 0.78 (0.63-0.97) | 0.73 (0.55- 0.98)

    PMID 40323973 · one of two readings recorded this

  • All-cause mortality

    no effect

    Gallwitz B | 2012 | Type 2 diabetes inadequately controlled on metformin | 2 | MACE, Death | 0.49(0.23-1.01) | 1.00 (0.14–7.07)

    PMID 40323973 · one of two readings recorded this

  • All-cause mortality

    no effect

    Ha KH | 2017 | Patients with DM-2 treated with metformin and an additional anti-diabetic agent. | 2.3 | Death | – | 0.84(0.66-1.07)

    PMID 40323973 · one of two readings recorded this

  • All-cause mortality

    no effect

    Her AY | 2024 | Type 2 diabetes patients with diabetes and acute myocardial infarction | 3 | MACE, Death | 0.48(0.12-1.90) | 0.72(0.41-1.27)

    PMID 40323973 · one of two readings recorded this

  • All-cause mortality

    decreases

    Hippisley-Cox J [51] | 2016 | Type 2 diabetes patients in second antidiabetic drug | 3 | Death | – | 0.62(0.55-0.71)

    PMID 40323973 · one of two readings recorded this

  • All-cause mortality

    no effect

    Hsu PF | 2018 | Type 2 diabetes inadequately controlled on metformin | 11 | MACE, Death | 0.78(0.69-0.88) | 0.956 (0.847–1.078)

    PMID 40323973 · one of two readings recorded this

  • All-cause mortality

    no effect

    Kannan S | 2016 | Patients with DM-2 treated with metformin and an additional anti-diabetic agent. | 4 | Death | – | 1.029 (0.81 - 1.31)

    PMID 40323973 · one of two readings recorded this

  • All-cause mortality

    no effect

    Kim KJ | 2019 | Type 2 diabetes patients in second antidiabetic drug | 1.63 | MACE, Death | 0.67(0.33-1.36) | 0.74(0.46-1.18)

    PMID 40323973 · one of two readings recorded this

  • All-cause mortality

    decreases

    Mogensen UM | 2014 | Type 2 diabetes inadequately controlled on metformin | 2.3 | MACE, Death | 0.57(0.40-0.80) | 0.57(0.40-0.80)

    PMID 40323973 · one of two readings recorded this

  • All-cause mortality

    decreases

    Morgan CL | 2014 | Type 2 diabetes were selected if initiated with combination therapies comprising metformin plus SUs or DPP-4is | 1.8 | MACE, Death | 0.64(0.45-0.93) | 0.67(0.49-0.91)

    PMID 40323973 · one of two readings recorded this

  • All-cause mortality

    decreases

    Ou HT | 2017 | All patients with T2Dwho initiated second-line treatment | 3.3 | MACE, Death | 0.82(0.69-0.97) | 0.82(0.69-0.99)

    PMID 40323973 · one of two readings recorded this

  • All-cause mortality

    decreases

    Ou SM | 2015 | All patients with Type 2 diabetes aged 20 years or older | 2.5 | MACE, Death | 0.67(0.59-0.78) | 0.63(0.55-0.72)

    PMID 40323973 · one of two readings recorded this

  • All-cause mortality

    no effect

    Thein D | 2020 | Type 2 diabetes patients in second antidiabetic drug | 2 | MACE, Death | 0.82(0.67-0.97) | 0.88(0.76-1.01)

    PMID 40323973 · one of two readings recorded this

  • All-cause mortality

    no effect

    Vaccaro O | 2017 | All patients with T2DM aged 50–75 years | 2 | MACE, Death | 0.83(0.54-1.29) | 1.10 (0·75–1·61)

    PMID 40323973 · one of two readings recorded this

  • All-cause mortality

    no effect

    Wang H | 2023 | Type 2 diabetes patients who received DPP-4is or SUs in addition to metformin | 2.7 | MACE, Death | 1.02(0.92-1.13) | 0.99(0.89-1.09)

    PMID 40323973 · one of two readings recorded this

  • All-cause mortality

    decreases

    Yu OH | 2015 | Type 2 diabetes inadequately controlled on metformin | 2 | Death | – | 0.53(0.29-0.97)

    PMID 40323973 · one of two readings recorded this

  • All-cause mortality

    no effect, p = 0.088

    Age average | <60 | 5 | 0.83(0.68-1.03) | 0.088

    PMID 40323973 · one of two readings recorded this

  • All-cause mortality

    decreases, p = 0.021

    Follow up time | ≤2 years | 6 | 0.81(0.68-0.97) | 0.021

    PMID 40323973 · one of two readings recorded this

  • All-cause mortality

    decreases, p = 0.029

    Quality assessment | Good quality | 7 | 0.78(0.62-0.97) | 0.029

    PMID 40323973 · one of two readings recorded this

  • All-cause mortality

    decreases, p = 0.001

    Moderate quality | 12 | 0.80(0.70-0.90) | ≤0.001

    PMID 40323973 · one of two readings recorded this

  • All-cause mortality

    decreases, p = 0.003

    Sample size | <3000 | 13 | 0.81(0.71-0.93) | 0.003

    PMID 40323973 · one of two readings recorded this

  • All-cause mortality

    decreases, p = 0.001

    Case- control | 1 | 0.57(0.40-0.81) | 0.001

    PMID 40323973 · one of two readings recorded this

  • All-cause mortality

    decreases, p = 0.001

    Cohort | 16 | 0.79(0.71-0.88) | ≤0.001

    PMID 40323973 · one of two readings recorded this

  • All-cause mortality

    no effect, p = 0.631

    Study design | RCT | 2 | 1.10(0.79-1.59) | 0.631

    PMID 40323973 · one of two readings recorded this

  • All-cause mortality

    no effect, p = 0.81

    Study location | America and Canada | 1 | 1.03(0.81-1.31) | 0.810

    PMID 40323973 · one of two readings recorded this

  • All-cause mortality

    decreases, p = 0.007

    Asia | 6 | 0.76(0.62-0.93) | 0.007

    PMID 40323973 · one of two readings recorded this

  • All-cause mortality

    decreases, p = 0.001

    Europe | 11 | 0.78(0.68-0.90) | 0.001

    PMID 40323973 · one of two readings recorded this

  • All-cause mortality

    no effect, p = 1

    International | 1 | 1(0.14-7.11) | 1.000

    PMID 40323973 · one of two readings recorded this

  • All-cause mortality

    decreases, p = 0.001

    Time period | 2017 or earlier | 8 | 0.68(0.59-0.78) | ≤0.001

    PMID 40323973 · one of two readings recorded this

  • All-cause mortality

    decreases, p = 0.004

    2018 or later | 11 | 0.90(0.84-0.97) | 0.004

    PMID 40323973 · one of two readings recorded this

  • MACE publication bias Begg's test

    no effect, p = 0.216

    Assessment for publication bias using Begg’s test (p = 0.216) and Egger’s test (p = 0.865)

    PMID 40323973 · one of two readings recorded this

  • MACE publication bias Egger's test

    no effect, p = 0.865

    Assessment for publication bias using Begg’s test (p = 0.216) and Egger’s test (p = 0.865)

    PMID 40323973 · one of two readings recorded this

  • MACE

    no effect

    Bazo-Alvarez JC | 2021 | Type 2 diabetes patients in second antidiabetic drug | 3.5 | MACE, Death | 0.94(0.81-1.10) | 0.97(0.81-1.16)

    PMID 40323973 · one of two readings recorded this

  • MACE

    no effect

    Chang YC | 2015 | Type 2 diabetes inadequately controlled on metformin | 0.74 | MACE | 0.90(0.74-1.04) | –

    PMID 40323973 · one of two readings recorded this

  • MACE

    decreases

    Franchi M | 2024 | Type 2 diabetes patients who received DPP-4is or SUs in addition to metformin | 5.61 | MACE, Death | 0.78 (0.63-0.97) | 0.73 (0.55- 0.98)

    PMID 40323973 · one of two readings recorded this

  • MACE

    no effect

    Gallwitz B | 2012 | Type 2 diabetes inadequately controlled on metformin | 2 | MACE, Death | 0.49(0.23-1.01) | 1.00 (0.14–7.07)

    PMID 40323973 · one of two readings recorded this

  • MACE

    no effect

    Gitt AK | 2013 | Patients with type 2 diabetes in which antidiabetic therapy was intensified | 1 | MACE | 1.26(0.44-3.56) | –

    PMID 40323973 · one of two readings recorded this

  • MACE

    no effect

    Her AY | 2024 | Type 2 diabetes patients with diabetes and acute myocardial infarction | 3 | MACE, Death | 0.48(0.12-1.90) | 0.72(0.41-1.27)

    PMID 40323973 · one of two readings recorded this

  • MACE

    decreases

    Hsu PF | 2018 | Type 2 diabetes inadequately controlled on metformin | 11 | MACE, Death | 0.78(0.69-0.88) | 0.956 (0.847–1.078)

    PMID 40323973 · one of two readings recorded this

  • MACE

    no effect

    Kim KJ | 2019 | Type 2 diabetes patients in second antidiabetic drug | 1.63 | MACE, Death | 0.67(0.33-1.36) | 0.74(0.46-1.18)

    PMID 40323973 · one of two readings recorded this

  • MACE

    decreases

    Mogensen UM | 2014 | Type 2 diabetes inadequately controlled on metformin | 2.3 | MACE, Death | 0.57(0.40-0.80) | 0.57(0.40-0.80)

    PMID 40323973 · one of two readings recorded this

  • MACE

    decreases

    Morgan CL | 2014 | Type 2 diabetes were selected if initiated with combination therapies comprising metformin plus SUs or DPP-4is | 1.8 | MACE, Death | 0.64(0.45-0.93) | 0.67(0.49-0.91)

    PMID 40323973 · one of two readings recorded this

  • MACE

    decreases

    O’Brien MJ | 2018 | All patients with T2Dwho initiated second-line treatment | 1.3 | MACE | 0.78(0.66-0.93) | –

    PMID 40323973 · one of two readings recorded this

  • MACE

    decreases

    Ou HT | 2017 | All patients with T2Dwho initiated second-line treatment | 3.3 | MACE, Death | 0.82(0.69-0.97) | 0.82(0.69-0.99)

    PMID 40323973 · one of two readings recorded this

  • MACE

    decreases

    Ou SM | 2015 | All patients with Type 2 diabetes aged 20 years or older | 2.5 | MACE, Death | 0.67(0.59-0.78) | 0.63(0.55-0.72)

    PMID 40323973 · one of two readings recorded this

The whole record — 946 rows